Pasithea Therapeutics

KTTA Rare disease Lead: Phase 1 3 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-30

Catalyst timeline

PAS-004 Ph1 topline2H 2026PAS-004 Ph1 topline, 2H 2026, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

PAS-004

Small Molecule Target: MEK 1, MEK 2, MEK

PAS-001

Small Molecule Target: C4A

Schizophrenia Preclinical

Discontinued (1)

PAS-003 — Amyotrophic Lateral Sclerosis · ceased further development due to significant capital, resources and time required to develop the program

Biotech Distilled coverage (3)

2026-06-30 UPDATE: Pasithea Therapeutics (KTTA) - The Macrocycle Earns Its Keep 🔒 Paid
2026-06-16 UPDATE: Pasithea Therapeutics (KTTA) - The Protocol Amendment Tax
2026-05-16 Pasithea Therapeutics (KTTA) - Scientific Deep Dive for PAS-004 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.